E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Mestastatic or locally advanced Epidermoid carcinoma of the head and neck |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine the relation between response rate and the number of CA repetition in the intron nr 1of the EGFR gene in patients with metastatic of locally advanced epidermoid head and neck carcinoma
|
|
E.2.2 | Secondary objectives of the trial |
To determine relation between number of CA repetition in intron 1of the EGFR gene and time to progression and survival in patients with metastatic or locally advanced epidermoid head-neck cancer To determine relation between frequency and intensity of coetaneous toxicity and other toxicities and nr of CA repetition in intron 1 of the EGFR gene in patients with metastatic or locally advanced epidermoid head-neck cancer To compare grade of regulation of the p27 protein and phosphorilation state of EGFR protein in coetaneous byopsias in patients with metastatic or locally advanced epidermoid head-neck cancer and with different nr of CA repetitions in intron 1 of the EGFR gene in treatment with erlotinib To determine relation between treatment with erlotinib and efficacy, toxicity and pharmacodymanic effects in patients with metastatic or locally advanced epidermoid head-neck cancer and with different number of CA repetitions in intron 1 of the EGFR gene in treatment with erlotinib.
|
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
Aceptation of the patiens to participate in the trial with their written consent prior to the commencement of the trial-related procedures. Patients with a histological proven diagnosis of cancer of head and neck incurable with other treatments of cirugy and radiotherapy.The nor distinghised carcinomas and not queratinizados as linfoepiteliomas in aereas of cancer of parotida glándula except: Patients with cancer de squamous cell WHO tipo I of nasofaringe. Ages 18-70 years Life-expectancy >12 weeks Measurable disease,RECIST criteria Fulfifment of the treatment and the patiens must be geographically accessible for treatment and follow-up. ECOG 0-2 If the patients have received a prior treatment: Chemotherapy: the patients musn,t have received more of 2 cycles of chemotherapy to the the treatment of the local disease and/or metastasic.The patients that have received the induction o chemoradiotherapy with a healing intention to local disease can participate in the trial if they have not received more of 2 cycles of chemotherapy to the recurrent disease. That treatment must have completed at least 14 days prior to the commencement of the trial.Every patients must have recovered of the toxic sever effects in relation with the prior treatment.The prior treatment of diana treatment such as inhibidores of tirosin quinasa and monoclonales antibodys. Radiotherapy:prior radiotherapy treatment is allowed if the patients have recovered of the toxic sever effects in relation the treatment before to start the trial.It must have been passed 14 days since the end of the radiotherapy treatment. The disease progression in a previous irradiated area must be demonstrated by byopsia or tomografic image. previous surgery: it is possible it the injury has healed and the surgery has been performed 14 days before the start of the trial TArget lesion >=20mm (or >=10mm CT spiral). If the area is a previous irradiated area it must be documented the disease progression or to be present a residual cancer demonstrated by byopsia Optima organic function according to: a)adequate medular function, ANC>1.5x109L, platelets>100x109L and hemoglobin>9g/dl b)adequate hepatic and renal function negative pregnancy test Good cardiovascular function
|
|
E.4 | Principal exclusion criteria |
Not writen informed consent. Another medical treatment with experimental drugs or another simultaneous chemotherapeutic drugs during the study. Patients with different histologic diagnosis of epidermoid carcinoma. Another previous neoplasia, except basal cell carcinoma or squamous carcinoma of skin, previous treated; resecate cervix carcinoma. Pregnant or lactancy women. Patiens with active infection Serious concomitant disease or patients with life expectancy smallest than their neoplasic disease. Serious psychiatric disease not controled. Patients unable to take oral medication or patients whose take intravenous food or patients with an intervention which interferes to the apsortion or patients with active peptic ulcer. Follow-up not possible. Symptomatic unstable metastasic brain, not controled with esteroids, life potential menace or with radiotherapy in the 14 days before the beginning of the study. Any disease, metabolic malfunction, abnormal physical exploration or analytic information who suggest an inconvenient condition for the administration of the trial medication that might affect the study results or increase the risk of patient treatment. Frequent vomits or medical disease who interferes to oral ingestion of medicaments. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
To determine the relation between response rate and the number of CA repetition in the intron nr 1of the EGFR gene in patients with metastatic of locally advanced epidermoid head and neck carcinoma
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 24 |
E.8.9.1 | In the Member State concerned days | |